Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

ospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of the initiation
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Astellas has appointed James Kellerman ... the Americas. Kellerman will report directly to Linda ... Astellas. In his new role, Kellerman will lead a ... and manage the region,s intellectual property matters, coordinating closely ... very pleased to welcome Jim to Astellas. Jim brings ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... Evolve Medical Clinics, the first ... urgent care arena, is having its Grand Opening ... health fair the clinic is sponsoring. Evolve offers ... patients in achieving high quality, convenient medical care. ... is a groundbreaking change in healthcare. The membership ...
(Date:9/2/2014)... September 02, 2014 Last year, SIGVARIS ... with the launch of a luxurious line of graduated compression ... the SEA ISLAND COTTON Socks are joining the SIGVARIS MEDICAL ... more people the comfort of natural cotton fibers. , ... are surprised to find socks as soft as the finest ...
(Date:9/2/2014)... Ticket Down is a reputable source ... September will be an exciting week for soccer fans in ... Ecuador and Bolivia will battle on U.S. soil in friendly ... September 5th - September 9th: , Brazil vs. Ecuador ... Mexico vs. Chile Tickets at Levi's Stadium on ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
Breaking Medicine News(10 mins):Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Can data motivate hospital leaders to improve care transitions? 2
... developed countries seem to be becoming ever more hectic. With ... reveals that Australian children in the 10-15 year age ... every nigth when compared with just one generation ago. ... television watching are to blame, with adolescents no longer adhering ...
... alcohol will be introduced in England to ward-off people from ... your limits and drink responsibly will be out by the ... ministers and industry. ,The agreement was first planned ... proper format has been adopted. ,Ministers have insisted ...
... extracted from the blood of bird flu survivors have helped ... virus. ,Scientists have long suspected that culling immune-system ... hard-to-treat H5N1 flu strain. ,If the research pans ... immune system's search-and-destroy force, as an additional way to treat ...
... by an American researcher has revealed that bricks made from ... might be safer than predicted. ,Rather than leach ... bricks do the reverse, pulling minute amounts of the toxic ... Henry Liu, a longtime National Science Foundation (NSF) awardee and ...
... tobacco industry for spreading untruths about smoking in public places ... bans around the world. ,The WHO said ... about the health risks and dangers of second-hand tobacco smoke ... ,"We all know that smoking kills," Shigeru Omi, director of ...
... inflammation are more likely to later develop Alzheimer's disease ... to a study published in the May 29, 2007, ... Academy of Neurology. ,The study, which is ... healthy people with an average age of 79. Blood ...
Cached Medicine News:Health News:Australian Children Sleep Less, Perhaps Not Well Monitored 2Health News:UK Introduce New Health Warnings Against Alcohol 2Health News:Blood from Bird Flu Survivors Provides Breakthrough in Treatment of H5N1 2Health News:Fly Ash Bricks are Absolutely Safer Than Actually Predicted 2Health News:WHO Condemns Tobacco Industry for Misleading Public 2
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used with permanent pacing leads....
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... the Tupos LV/A+, the single-lead principle has been ... time. The complete system, which consists of the ... minimizes the scope of surgery and the risk ... atrium and the ventricle via a single lead. ...
Medicine Products: